IL103852A - Method and kit for detecting antibodies in the blood with a negative serum of people - Google Patents
Method and kit for detecting antibodies in the blood with a negative serum of peopleInfo
- Publication number
- IL103852A IL103852A IL10385292A IL10385292A IL103852A IL 103852 A IL103852 A IL 103852A IL 10385292 A IL10385292 A IL 10385292A IL 10385292 A IL10385292 A IL 10385292A IL 103852 A IL103852 A IL 103852A
- Authority
- IL
- Israel
- Prior art keywords
- kit
- virus
- mitogen
- container
- antigen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 238000001514 detection method Methods 0.000 title claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 84
- 210000004369 blood Anatomy 0.000 claims abstract description 80
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 33
- 238000003556 assay Methods 0.000 claims abstract description 26
- 239000003226 mitogen Substances 0.000 claims abstract description 26
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 38
- 241000700605 Viruses Species 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 20
- 238000002965 ELISA Methods 0.000 claims description 17
- 108010033737 Pokeweed Mitogens Proteins 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 13
- 238000001262 western blot Methods 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 4
- 238000010166 immunofluorescence Methods 0.000 claims description 4
- 108090001090 Lectins Proteins 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 239000002523 lectin Substances 0.000 claims description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 239000007769 metal material Substances 0.000 claims 2
- 230000010460 detection of virus Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 11
- 208000031886 HIV Infections Diseases 0.000 abstract description 10
- 238000012216 screening Methods 0.000 abstract description 5
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 3
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 2
- 102000018358 immunoglobulin Human genes 0.000 abstract description 2
- 239000012503 blood component Substances 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 16
- 239000012530 fluid Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 241000282693 Cercopithecidae Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 241000713311 Simian immunodeficiency virus Species 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 208000008771 Lymphadenopathy Diseases 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 206010001513 AIDS related complex Diseases 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 208000005074 Retroviridae Infections Diseases 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000018555 lymphatic system disease Diseases 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 240000007643 Phytolacca americana Species 0.000 description 2
- 235000009074 Phytolacca americana Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- -1 such as Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 206010000159 Abnormal loss of weight Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 239000007757 Media 199 Substances 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- AIDS & HIV (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Prostheses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79773091A | 1991-11-25 | 1991-11-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL103852A0 IL103852A0 (en) | 1993-04-04 |
| IL103852A true IL103852A (en) | 1999-06-20 |
Family
ID=25171653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10385292A IL103852A (en) | 1991-11-25 | 1992-11-24 | Method and kit for detecting antibodies in the blood with a negative serum of people |
| IL12533098A IL125330A0 (en) | 1991-11-25 | 1998-07-13 | Method of matching tissue for transplantation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12533098A IL125330A0 (en) | 1991-11-25 | 1998-07-13 | Method of matching tissue for transplantation |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5637453A (de) |
| EP (1) | EP0643838B1 (de) |
| JP (2) | JPH07509557A (de) |
| AT (1) | ATE191791T1 (de) |
| CA (2) | CA2200363A1 (de) |
| DE (1) | DE69230918T2 (de) |
| DK (1) | DK0643838T3 (de) |
| ES (1) | ES2147195T3 (de) |
| GR (1) | GR3033919T3 (de) |
| IL (2) | IL103852A (de) |
| PT (1) | PT643838E (de) |
| WO (1) | WO1993011435A1 (de) |
| ZA (1) | ZA929160B (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6280962B1 (en) | 1991-11-25 | 2001-08-28 | Yoreh Biotechnologies Ltd. | Whole blood/mitogen assay for the early detection of a subject with cancer and kit |
| US6352826B1 (en) | 1991-11-25 | 2002-03-05 | Yoreh Biotechnologies, Ltd. | Method and kit for the detection of retroviral specific antibodies in seronegative individuals |
| US6322989B1 (en) | 1991-11-25 | 2001-11-27 | Yoreh Biotechnologies, Ltd. | Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit |
| JP2001504233A (ja) * | 1996-11-22 | 2001-03-27 | シルーヴ メディカル テクノロジーズ リミテッド | 癌を有する被験者の早期検出のための全血/マイトジェンアッセイおよびキット |
| EP0973944A1 (de) * | 1997-03-31 | 2000-01-26 | Abbott Laboratories | Reagentien und verfahren zur erkennung von krankheiten des gastrointestinaltraktes |
| WO1998044160A1 (en) * | 1997-03-31 | 1998-10-08 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the gastrointestinal tract |
| GB9913819D0 (en) | 1999-06-14 | 1999-08-11 | Plasmacute As | Assay |
| DE10125730A1 (de) * | 2001-05-17 | 2002-11-21 | A I D Autoimmun Diagnostika Gm | Verfahren zum Nachweis von Erregern und durch diese induzierten zellulär produzierten Stoffen im lebenden Organismus |
| WO2004064608A2 (en) * | 2003-01-17 | 2004-08-05 | Aethlon Medical, Inc. | Method for removal of viruses from blood by lectin affinity hemodialysis |
| GB0325483D0 (en) * | 2003-10-31 | 2003-12-03 | Plasmacute As | Assay |
| EP2309269B1 (de) * | 2004-09-08 | 2016-10-26 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Zusammensetzungen und verfahren zur detektion von hiv-1/hiv-2 infektion |
| US7770050B2 (en) * | 2006-05-03 | 2010-08-03 | Sony Computer Entertainment Inc. | Method and apparatus for resolving clock management issues in emulation involving both interpreted and translated code |
| CA2810770A1 (en) * | 2010-09-07 | 2012-03-15 | Smart Biotech Ltd. | Methods and kits for the detection of an infection in subjects with low specific antibody levels |
| BR112013024317A2 (pt) * | 2011-03-23 | 2019-09-24 | Smart Biotech Ltd | método e kit para a determinação do tempo de seroconversão de um paciente infectado com um vírus |
| US9651557B2 (en) * | 2012-03-08 | 2017-05-16 | Dror Atzmon | Method and kit for the detection of hepatitis-specific antibodies |
| WO2013132496A1 (en) * | 2012-03-08 | 2013-09-12 | Smart Biotech Ltd. | Methods and kits for the detection of viral infections |
| WO2016014861A1 (en) * | 2014-07-25 | 2016-01-28 | Incelldx, Inc. | Methods of evaluating a cellular sample for latent cellular replication competent hiv-1, and compositions and kits for use in practicing the same |
| DE102019214137A1 (de) * | 2019-09-17 | 2021-03-18 | Hot Screen Gmbh | Verwendung in vitro eines Kits und eines Verfahrens zur Diagnostik von Transplantationen und/oder Autoimmunerkrankungen und/oder Tumorerkrankungen und/oder Vakzinierungen sowie ein botenstoffhaltiger Überstand, zellhaltiges Sediment und eine Kombination zur Anwendung bei der Diagnostik von Transplantationen und/oder Autoimmunerkrankungen und/oder Tumorerkrankungen und/oder Vakzinierungen |
| CN113917162B (zh) * | 2021-12-14 | 2022-04-01 | 江苏为真生物医药技术股份有限公司 | 去唾液酸糖蛋白受体片段sH2a作为标志物的应用 |
-
1992
- 1992-11-24 CA CA002200363A patent/CA2200363A1/en not_active Abandoned
- 1992-11-24 PT PT93900599T patent/PT643838E/pt unknown
- 1992-11-24 AT AT93900599T patent/ATE191791T1/de active
- 1992-11-24 DE DE69230918T patent/DE69230918T2/de not_active Expired - Fee Related
- 1992-11-24 DK DK93900599T patent/DK0643838T3/da active
- 1992-11-24 ES ES93900599T patent/ES2147195T3/es not_active Expired - Lifetime
- 1992-11-24 IL IL10385292A patent/IL103852A/en not_active IP Right Cessation
- 1992-11-24 EP EP93900599A patent/EP0643838B1/de not_active Expired - Lifetime
- 1992-11-24 CA CA002124319A patent/CA2124319A1/en not_active Abandoned
- 1992-11-24 WO PCT/US1992/010075 patent/WO1993011435A1/en not_active Ceased
- 1992-11-24 JP JP5510189A patent/JPH07509557A/ja active Pending
- 1992-11-25 ZA ZA929160A patent/ZA929160B/xx unknown
-
1994
- 1994-07-15 US US08/275,933 patent/US5637453A/en not_active Expired - Lifetime
-
1996
- 1996-11-22 US US08/755,287 patent/US20020006608A1/en not_active Abandoned
-
1998
- 1998-07-13 IL IL12533098A patent/IL125330A0/xx unknown
- 1998-10-20 JP JP10298800A patent/JPH11237381A/ja active Pending
-
2000
- 2000-07-10 GR GR20000401604T patent/GR3033919T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE191791T1 (de) | 2000-04-15 |
| JPH07509557A (ja) | 1995-10-19 |
| EP0643838A4 (de) | 1996-02-28 |
| WO1993011435A1 (en) | 1993-06-10 |
| EP0643838B1 (de) | 2000-04-12 |
| DE69230918D1 (de) | 2000-05-18 |
| US5637453A (en) | 1997-06-10 |
| CA2200363A1 (en) | 1993-05-26 |
| JPH11237381A (ja) | 1999-08-31 |
| EP0643838A1 (de) | 1995-03-22 |
| US20020006608A1 (en) | 2002-01-17 |
| IL125330A0 (en) | 1999-08-17 |
| CA2124319A1 (en) | 1993-06-10 |
| IL103852A0 (en) | 1993-04-04 |
| ES2147195T3 (es) | 2000-09-01 |
| GR3033919T3 (en) | 2000-11-30 |
| DK0643838T3 (da) | 2000-09-11 |
| DE69230918T2 (de) | 2000-11-09 |
| ZA929160B (en) | 1993-08-16 |
| PT643838E (pt) | 2000-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5637453A (en) | Whole blood method and kit for the detection of antibodies against human immunodeficiency virus (HIV) in HIV-seronegative individuals | |
| JP2729212B2 (ja) | Hivの精製単離されたレトロウィルス | |
| WITTEK et al. | Detection of human immunodeficiency virus core protein in plasma by enzyme immunoassay: association of antigenemia with symptomatic disease and T-helper cell depletion | |
| US4904581A (en) | Method of detecting AIDS virus infection | |
| US5773232A (en) | Methods for measurement of lymphocyte function | |
| US4968601A (en) | Method for diagnosing latent viral infection | |
| US6352826B1 (en) | Method and kit for the detection of retroviral specific antibodies in seronegative individuals | |
| US4917998A (en) | Method of detecting AIDS virus infection | |
| US20010008760A1 (en) | Reagent system and kit for detecting hiv infected cells | |
| Prince et al. | Immunologic correlates of spontaneous lymphocyte proliferation in human T-lymphotropic virus infection | |
| EP0196873B1 (de) | Diagnose für Mikroorganismen | |
| US6306581B1 (en) | Diagnostic assay method and kit for the detection of HHV-8 infection | |
| AU743937B2 (en) | Reagent system and kit for detecting HIV infected cells | |
| US7169571B2 (en) | Methods for measurement of lymphocyte function | |
| De Stasio et al. | Screening for anti-human T-lymphotropic virus antibody in blood donors and polytransfused patients in Apulia (Italy) | |
| EP0220970B1 (de) | Methoden zur Verwendung von an humanen Klasse-II-Histokompatibilitätsantigenen mangelnden Zellinien | |
| Prince et al. | Lymphocyte subsets in HTLV-II-infected former blood donors: relationship to spontaneous lymphocyte proliferation | |
| Roberts | Laboratory diagnosis of retroviral infections | |
| EP0514494B1 (de) | Verfahren zum nachweis des humanen immunodeficiency virus (hiv) und dafür geeignete zellinien | |
| US5580772A (en) | Association between a novel human intracisternal A-type retroviral particle-type II (HIAP-II) and idiopathic CD4+ T-lymphocytopenia (ICL) | |
| JPH05188057A (ja) | Hiv−1抗体の免疫酵素的検出法 | |
| WO1993010222A1 (en) | New human intracisternal retrovirus associated with cd4+ t cell deficiency/dysfunction | |
| Ovčak et al. | Evaluation of EIA kits for the detection of HIV antibodies. | |
| Howanitz et al. | Assessment of biological reagents for presence of human immunodeficiency virus-1 (HIV-1) antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| RH1 | Patent not in force |